Title: "Unraveling the Complexity of Superantigen Exotoxins: Structure, Function, and Therapeutic

Implications"

I. Introduction

A. Definition of Superantigen Exotoxins

Superantigen exotoxins are powerful virulence factors produced by some bacterial infections, most
notably Staphylococcus aureus and Streptococcus pyogenes (group A streptococci). These poisons have
the unique capacity to interact with the immune system in an unexpected way. Unlike normal antigens,
which activate a specific fraction of T cells, superantigens excite a significant proportion of T cells,
regardless of the antigen specificity (Fleischer & Fleischer, 1994). This indiscriminate activation happens
when superantigens connect to MHC class II molecules on antigen-presenting cells and then cross-link
with T cell receptors. The hyperactivation of T cells results in the enormous production of
proinflammatory cytokines, generating systemic inflammation and possibly serious pathological
repercussions for the host (L Mojahed Asl, 2019) .

B. Importance of Studying Superantigen Exotoxins

Understanding the structure and function of superantigen exotoxins is critical for determining the
processes that underpin bacterial pathogenicity and immune evasion. These toxins play an important
role in the development of numerous infectious illnesses, ranging from simple skin infections to life-
threatening situations like toxic shock syndrome (Miller et al., 2020; Miwa et al., 2006) . Furthermore,
the evolution of antibiotic-resistant species highlights the importance of developing alternative
treatment techniques that target bacterial virulence factors such as superantigens. Thus, investigating
superantigen exotoxins is critical for influencing the creation of innovative treatment modalities and
vaccines targeted at efficiently treating bacterial infections (McCormick et al., 2001; McKay et al., 2000)
.

Figure 1 Superantigen brief overview

C. Overview of Staphylococcus aureus and Streptococcus pyogenes

Staphylococcus aureus and Streptococcus pyogenes are Gram-positive bacteria commonly found as
commensals on human skin and mucous membranes. While they can coexist harmlessly with their host,
under certain conditions, they can cause a wide range of infections. Superantigen exotoxins produced by
these bacteria contribute significantly to their pathogenicity
(Matsubara & Fukaya, 2007; Mattis et al., 2013)
. Staphylococcus aureus exotoxins, including toxic shock syndrome toxin-1 (TSST-1) and
staphylococcal enterotoxins (SEs), are associated with conditions such as toxic shock syndrome and food
poisoning (Martín et al., 2004) . Streptococcus pyogenes produces streptococcal pyrogenic exotoxins
(SPEs), which are implicated in severe invasive infections like necrotizing fasciitis and streptococcal toxic
shock syndrome. Understanding the structure and function of superantigen exotoxins from these
pathogens is crucial for devising effective strategies to combat their associated diseases
(Ma et al., 2004; Maina et al., 2012)
.

II. Superantigen Exotoxins: General Characteristics

A. Molecular Mass and Physical Properties

Superantigen exotoxins have a low molecular mass, often ranging from 19 to 30 kDa. Despite their tiny
size, these poisons are very stable and resistant to environmental conditions such as heat, acid, and
proteolysis. This resilience enables superantigen exotoxins to continue their biological activity under a
variety of physiological settings, making them effective mediators of immunological dysregulation and
inflammatory responses (S. J. Li et al., 2011a; T. Li et al., 2017)
.

Figure 2 Super antigen structure

B. Mechanism of Action: Overstimulation of the Immune System

Superantigen exotoxins are distinguished by their capacity to cause polyclonal activation of T cells by
crosslinking MHC class II molecules on antigen-presenting cells with T cell receptors (TCRs) on T cells.
Superantigens directly engage T cells with particular TCR Vβ regions, unlike ordinary antigens that
activate T cells through peptide identification by MHC molecules
(Leuenberger et al., 2019; Leung et al., 1995)
. This promiscuous activation leads to the massive release of proinflammatory cytokines, such as
interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ), resulting in
systemic inflammation and tissue damage (Krakauer, 2019; Lee et al., 1991) .

C. Implications for Host Pathology

The dysregulated immune response caused by superantigen exotoxins can have serious clinical
implications, ranging from moderate fever and inflammation to severe toxic shock syndrome and
multiple organ dysfunction syndrome. Superantigen-induced systemic cytokine release can cause
hypotension, capillary leakage, and organ failure, all of which can be life-threatening. Furthermore,
continuous exposure to superantigens may lead to the development of autoimmune illnesses and
chronic inflammatory diseases, emphasizing the clinical relevance of superantigen-mediated immune
dysregulation (Kim et al., 2019; Kozono et al., 1995)
.

III. Structure of Superantigen Exotoxins

A. General Structure of Superantigen Exotoxins

Superantigen exotoxins, which are generated by bacteria like Staphylococcus aureus and Streptococcus
pyogenes, have a conserved structural motif despite differences in basic sequence. These poisons often
fold into a tight, spherical shape that is stabilized by disulfide links. The tertiary structure of
superantigen exotoxins is critical for their biological activity because it dictates their capacity to connect
with host immune receptors and activate immune cells. Despite having a shared basic topology,
superantigens may have distinct structural characteristics that contribute to their functional variety and
antigenic specificity (Kérouanton et al., 2007).

B. Structural Features Specific to Staphylococcus aureus Exotoxins

Staphylococcus aureus generates a number of superantigen exotoxins, including TSST-1, staphylococcal

enterotoxins (SEs), and staphylococcal exfoliative toxins (ETA and ETB). These exotoxins have different
structural properties that are relevant to their involvement in bacterial pathogenesis. SEB and SEC have
a "Jelly Roll" fold with two antiparallel β-sheets packed together, while TSST-1 has a β-barrel structure
with disulfide links for stability. These structural changes provide distinct functional features and
antigenic specificities to staphylococcal superantigens, altering their interaction with host immune
receptors and contributing to disease pathogenesis (Katsuda et al., 2005).

Figure 3 Superantigen recognition, interaction and mechanism

C. Structural Features Specific to Streptococcus pyogenes Exotoxins

Streptococcus pyogenes produces a type of superantigen exotoxins known as streptococcal pyrogenic

exotoxins (SPEs), which play an important role in the development of severe streptococcal infections.
SPEs are structurally similar to staphylococcal enterotoxins but have distinct sequence variants that give
species-specificity and functional diversity. SPEs engage with different fractions of T cell receptor Vβ
regions than staphylococcal superantigens, leading to varying T cell activation and cytokine production.
The discovery of SPEs' three-dimensional structures has offered vital insights into their molecular
interactions with host immune receptors and allowed the formulation of tailored therapeutic
approaches for streptococcal infections (Kappler et al., 1989; Kato et al., 2011).

IV. Function of Superantigen Exotoxins

A. Interaction with Host Immune System

Superantigen exotoxins interact with a variety of host immune system components, resulting in
dysregulated immune responses and inflammatory cascades. These poisons typically target antigen-
presenting cells (APCs), such as dendritic cells and macrophages, by attaching to MHC class II molecules
on their surfaces. Superantigens activate a significant proportion of T cells, regardless of antigen
specificity, by cross-linking MHC class II molecules to T cell receptors (TCRs) on T cells. This promiscuous
activation leads to the release of proinflammatory cytokines and chemokines, which causes systemic
inflammation and tissue damage (Jiang et al., 2019; Jupin et al., 1988).

B. Effects of Overstimulation on the Host

Superantigen exotoxins activate T cells polyclonally, resulting in high levels of cytokines such IL-1, TNF-α,
and IFN-γ. These cytokines promote systemic inflammation and tissue damage, which contribute to the
pathophysiology of illnesses linked with superantigen exposure. Toxic shock syndrome (TSS) and
multiple organ dysfunction syndrome (MODS) are severe symptoms of superantigen-mediated immune
dysregulation, including hypotension, capillary leakage, and organ failure. Additionally, continuous
exposure to superantigens may accelerate the development of autoimmune illnesses and chronic
inflammatory diseases, emphasizing the long-term repercussions of immunological dysregulation
(Hu et al., 2007)
.

C. Contribution to Pathogenicity of Staphylococcus aureus and Streptococcus pyogenes

Staphylococcus aureus and Streptococcus pyogenes infections are characterized by the presence of
superantigen exotoxins. These toxins help bacteria colonize, invade tissues, and evade the immune
system, all of which contribute to the severity and outcome of infectious illnesses. Staphylococcal
superantigens, including toxic shock syndrome toxin-1 (TSST-1) and staphylococcal enterotoxins (SEs),
have been linked to toxic shock syndrome and food poisoning. Streptococcal pyrogenic exotoxins (SPEs),
which are generated by Streptococcus pyogenes, lead to severe invasive infections such necrotizing
fasciitis and streptococcal toxic shock syndrome. Targeting superantigen-mediated immune
dysregulation is a viable method for developing innovative therapeutic approaches targeted at
minimizing the pathogenic consequences of Staphylococcus aureus and Streptococcus pyogenes
infections (Hu et al., 2003).

V. Biochemical Aspects of Superantigen Exotoxins

A. Structure-Function Relationship
The complex link between the structure and function of superantigen exotoxins is the focus of
biochemical research. Researchers are working to understand how the precise structural properties of
these toxins influence their potential to engage with host immune receptors and cause immunological
dysregulation. High-resolution structural investigations, including as X-ray crystallography and nuclear
magnetic resonance (NMR) spectroscopy, have revealed important details about the three-dimensional
architecture of superantigen exotoxins. By identifying key residues involved in receptor binding and T
cell activation, scientists hope to elucidate the molecular processes underpinning superantigen-
mediated immunological stimulation (Hoekstra et al., 2020).

B. Post-Translational Modifications

Post-translational changes significantly influence the biological activity and stability of superantigen
exotoxins. Signal peptide cleavage and disulfide bond formation are two important post-translational
activities that occur during the development of these poisons. Disulfide bonds, in particular, contribute
to the structural integrity of superantigens, ensuring their stability and function. Understanding the
influence of post-translational changes on the structure-function connection of superantigen exotoxins
is critical for unravelling their pathogenic potential and developing targeted treatment methods
(Haveri et al., 2005)
.

C. Immunomodulatory Mechanisms

Superantigen exotoxins use a range of immunomodulatory mechanisms to disrupt host immune

responses and increase bacterial survival. By hijacking the host immune system, these toxins generate a
proinflammatory milieu that promotes bacterial growth and dispersion. Furthermore, superantigens
may disrupt regulatory pathways involved in immunological tolerance and homeostasis, worsening
immune dysfunction and tissue damage. Understanding the complicated interplay between
superantigen exotoxins and host immune cells is crucial for discovering novel therapeutic targets and
creating immunomodulatory techniques to attenuate the pathogenic consequences of bacterial
infections (GUSS et al., 1984)
.

D. Therapeutic Implications

The biochemical analysis of superantigen exotoxins has important therapeutic implications for the
treatment of bacterial infections. Researchers hope to develop new inhibitors that can limit the
interaction of these poisons with host immunological receptors by targeting crucial structural features
or functional domains. Furthermore, immunomodulatory drugs that can modulate the host immune
response to superantigens offer a prospective path for therapeutic intervention. Furthermore, the
development of vaccines targeting superantigen exotoxins might provide long-term protection against
bacterial infections and lower the occurrence of related disorders
(Günther et al., 2007; Hall et al., 1999)
.

VI. Pathogenic Aspects of Superantigen Exotoxins

A. Host-Pathogen Interactions

Superantigen exotoxins play an important part in the complex interaction between bacterial pathogens
and the host immune system. These toxins use host immunological receptors and signalling pathways to
aid bacterial survival, spread, and immune evasion. Superantigens promote bacterial colonisation and
tissue invasion by increasing cytokine production and disrupting immune responses. Furthermore,
superantigen-mediated immune dysregulation can cause severe systemic consequences, such as toxic
shock syndrome and multiple organ dysfunction syndrome (Fisher et al., 2018; Fitzgerald et al., 2001).

B. Disease Associations

Superantigen exotoxins are linked to a variety of infectious illnesses produced by Staphylococcus aureus
and Streptococcus pyogenes. Staphylococcal superantigens, including toxic shock syndrome toxin-1
(TSST-1) and staphylococcal enterotoxins (SEs), have been linked to toxic shock syndrome,
staphylococcal scalded skin syndrome, and food poisoning. Streptococcal pyrogenic exotoxins (SPEs)
generated by Streptococcus pyogenes are linked to severe invasive infections such as necrotizing fasciitis
and streptococcal toxic shock syndrome. The many clinical presentations of superantigen-mediated
illnesses highlight the varied nature of host-pathogen interactions and the need of understanding the
pathogenic processes that underpin these infections (Edwin & Kass, 1989; Fang et al., 2019) .

C. Impact on Public Health

The widespread presence of superantigen-producing bacterial strains raises serious public health
concerns. Outbreaks of superantigen-mediated illnesses, such as toxic shock syndrome caused by
tampon usage or surgical wound infections, show the pathogens' ability to spread rapidly throughout
populations. Furthermore, the rise of antibiotic-resistant strains complicates the management of
superantigen-related illnesses, emphasising the need for novel therapeutic methods. Efforts to improve
monitoring, infection control measures, and vaccine development are vital for reducing the public health
effect of superantigen generating microorganisms (Dobretsov et al., 2019; Edwards et al., 2012).
D. Future Directions

Future research prospects in superantigen exotoxins include a wide range of multidisciplinary

techniques aiming at understanding the intricacies of host-pathogen interactions and generating novel
disease preventive and treatment strategies. Advances in genomic, proteomic, and immunological
approaches provide unparalleled opportunity to understand the molecular processes driving
superantigen-mediated disease and uncover new targets for therapeutic intervention. Furthermore,
joint efforts among academics, doctors, and public health authorities are vital for converting scientific
insights into real solutions to prevent superantigen-related disorders and protect public health
(Deringer et al., 1997)
.
VII. Therapeutic Strategies Targeting Superantigen Exotoxins

A. Antibody-Based Therapies

One possible therapeutic method is the creation of monoclonal antibodies that target superantigen
exotoxins. These antibodies can neutralize the action of toxins by preventing them from attaching to
host immunological receptors or facilitating their removal from the body. Several monoclonal antibodies
against staphylococcal and streptococcal superantigens have demonstrated effectiveness in preclinical
investigations and clinical trials, suggesting their promise for the treatment of superantigen-mediated
illnesses (Couch et al., 1988; Dauwalder et al., 2006).
B. Small Molecule Inhibitors

Small molecule inhibitors provide another path for treating superantigen exotoxins. These chemicals
target particular structural features or functional domains of toxins, preventing them from interacting
with host immunological receptors and limiting their biological activity. High-throughput screening and
structure-based drug design methodologies have enabled the discovery of prospective small molecule
inhibitors with promising inhibitory effects on staphylococcal and streptococcal superantigens
(Collery et al., 2009)
.
C. Immunomodulatory Agents

Immunomodulatory drugs that can modulate host immune responses to superantigen exotoxins provide
an alternative treatment method for superantigen-mediated illnesses. These medicines may target
signaling pathways involved in cytokine generation, immune cell activation, or inflammatory responses,
reducing superantigens' detrimental impact on the host immune system. Immunomodulatory
treatments have the potential to reduce the systemic problems associated with superantigen exposure
while also improving clinical outcomes in afflicted people (Choi et al., 1990; Coleman et al., 1989).
D. Vaccine Development

Vaccine development is a long-term strategy for avoiding superantigen-mediated illnesses and lowering
the prevalence of bacterial infections caused by Staphylococcus aureus and Streptococcus pyogenes.
Vaccines aimed targeted superantigen exotoxins seek to elicit protective immune responses against
these toxins, blocking their binding to host immune receptors and consequent immunological
dysregulation. Several vaccine options, including toxoid-based vaccines and subunit vaccinations, are
being developed and evaluated in preclinical and clinical investigations, with the ultimate objective of
giving permanent protection against superantigen-producing bacterial infections (Cheng et al., 2017).
VIII. Conclusion and Future Perspectives

A. Recapitulation of Key Points

In this comprehensive analysis, we looked at the structure, function, pathogenicity, and therapeutic
applications of superantigen exotoxins generated by Staphylococcus aureus and Streptococcus
pyogenes. These virulence factors have distinct biochemical and immunomodulatory capabilities that
allow them to disrupt host immune responses and contribute to the development of infectious illnesses.
Superantigen exotoxins interact with multiple host immune system components, causing dysregulated
immunological activation, systemic inflammation, and tissue damage. The understanding of the
structural characteristics and immunomodulatory processes of superantigens has offered vital insights
into their involvement in bacterial pathogenesis, facilitating the development of targeted treatment
therapies (Argudín et al., 2010; Pascual & Capra, 1991)
.
B. Implications for Research and Clinical Practice

Future research on superantigen exotoxins has the potential to significantly advance our understanding
of bacterial pathogenesis and immunological dysregulation. Continued research into the molecular
processes driving superantigen-mediated immune activation and tissue harm will pave the way for the
development of new therapeutic options for treating infectious illnesses caused by Staphylococcus
aureus and Streptococcus pyogenes. Furthermore, the translation of scientific discoveries into clinical
practice will require coordinated multidisciplinary approaches combining fundamental scientists,
physicians, and public health specialists (Deacy et al., 2021).
C. Emerging Challenges and Opportunities

Despite tremendous advances in our understanding of superantigen exotoxins, various difficulties and
possibilities remain. The rise of antibiotic-resistant strains, as well as the rising prevalence of
superantigen-related disorders, highlight the critical need for alternate treatment methods and efficient
infection control strategies. Furthermore, developing vaccinations against superantigens is a viable
technique for avoiding bacterial infections and lowering the burden of related disorders. However, the
design and execution of successful vaccinations encounter problems such as antigenic diversity,
immunogenicity, and vaccine administration (S. J. Li et al., 2011b) .
 D. Directions for Future Research

Future research should concentrate on understanding the host-pathogen interactions that underpin
superantigen-mediated illnesses and discovering new therapeutic targets for intervention. Advances in
genomic, proteomic, and immunological approaches provide unparalleled opportunity to investigate the
molecular pathways underlying bacterial disease and immune dysregulation. Furthermore, coordinated
multicenter investigations and clinical trials are necessary to evaluate the effectiveness and safety of
innovative treatment approaches in varied patient groups and clinical contexts (Bachert et al., 2010).
References

Argudín, M. Á., Mendoza, M. C., & Rodicio, M. R. (2010). Food Poisoning and Staphylococcus aureus
Enterotoxins. Toxins, 2(7), 1751–1773. https://doi.org/10.3390/TOXINS2071751

Bachert, C., Zhang, N., Holtappels, G., De Lobel, L., Van Cauwenberge, P., Liu, S., Lin, P., Bousquet, J., & Van
Steen, K. (2010). Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal
polyps is associated with comorbid asthma. The Journal of Allergy and Clinical Immunology, 126(5), 962–
968. https://doi.org/10.1016/j.jaci.2010.07.007

Cheng, K. J., Xu, Y. Y., Zhou, M. L., Zhou, S. H., & Wang, S. Q. (2017). Role of local allergic inflammation and
Staphylococcus aureus enterotoxins in Chinese patients with chronic rhinosinusitis with nasal polyps. The
Journal of Laryngology and Otology, 131(8), 707–713. https://doi.org/10.1017/s0022215117001335

Choi, Y., Herman, A., DiGiusto, D., Wade, T., Marrack, P., & Kappler, J. (1990). Residues of the variable region of
the T-cell-receptor β-chain that interact with S. aureus toxin superantigens. Nature, 346(6283), 471–473.
https://doi.org/10.1038/346471a0

Coleman, D. C., Sullivan, D. J., Russell, R. J., Arbuthnott, J. P., Carey, B. F., & Pomeroy, H. M. (1989).
Staphylococcus aureus bacteriophages mediating the simultaneous lysogenic conversion of beta-lysin,
staphylokinase and enterotoxin A: Molecular mechanism of triple conversion. Journal of General
Microbiology, 135(6), 1679–1697. https://doi.org/10.1099/00221287-135-6-1679

Collery, M. M., Smyth, D. S., Tumilty, J. J. G., Twohig, J. M., & Smyth, C. J. (2009). Associations between
enterotoxin gene cluster types egc1, egc2 and egc3, agr types, enterotoxin and enterotoxin-like gene
profiles, and molecular typing characteristics of human nasal carriage and animal isolates of
Staphylococcus aureus. Journal of Medical Microbiology, 58(1), 13–25.
https://doi.org/10.1099/JMM.0.005215-0

Couch, J. L., Soltis, M. T., & Betley, M. J. (1988). Cloning and nucleotide sequence of the type E staphylococcal
enterotoxin gene. Journal of Bacteriology, 170(7), 2954–2960. https://doi.org/10.1128/jb.170.7.2954-
2960.1988

Dauwalder, O., Thomas, D., Ferry, T., Debard, A.-L., Badiou, C., Vandenesch, F., Etienne, J., Lina, G., &
Monneret, G. (2006). Comparative inflammatory properties of staphylococcal superantigenic
enterotoxins SEA and SEG: Implications for septic shock. Journal of Leukocyte Biology, 80(4), 753–758.
https://doi.org/10.1189/jlb.0306232

Deacy, A. M., Gan, S. K. E., & Derrick, J. P. (2021). Superantigen Recognition and Interactions: Functions,
Mechanisms and Applications. Frontiers in Immunology, 12, 731845.
https://doi.org/10.3389/FIMMU.2021.731845/BIBTEX
Deringer, J. R., Ely, R. J., Monday, S. R., Stauffacher, C. V., & Bohach, G. A. (1997). Vbeta-dependent stimulation
of bovine and human T cells by host-specific staphylococcal enterotoxins. Infection and Immunity,
65(10), 4048–4054. https://doi.org/10.1128/iai.65.10.4048-4054.1997

Dobretsov, K., Negm, H., Ralli, M., & Passali, D. (2019). The theory of a “Staphylococcus superantigen” in
chronic rhinosinusitis with nasal polyps: Myth or reality? European Review for Medical and
Pharmacological Sciences, 23(1 Suppl), 48–54. https://doi.org/10.26355/eurrev_201903_17349

Edwards, L. A., O’Neill, C., Furman, M. A., Hicks, S., Torrente, F., Pérez-Machado, M., Wellington, E. M., Phillips,
A. D., & Murch, S. H. (2012). Enterotoxin-producing staphylococci cause intestinal inflammation by a
combination of direct epithelial cytopathy and superantigen-mediated T-cell activation. Inflammatory
Bowel Diseases, 18(4), 624–640. https://doi.org/10.1002/ibd.21852

Edwin, C., & Kass, E. H. (1989). Identification of functional antigenic segments of toxic shock syndrome toxin 1
by differential immunoreactivity and by differential mitogenic responses of human peripheral blood
mononuclear cells, using active toxin fragments. Infection and Immunity, 57(7), 2230–2236.
https://doi.org/10.1128/iai.57.7.2230-2236.1989

Fang, R., Cui, J., Cui, T., Guo, H., Ono, H. K., Park, C. H., Okamura, M., Nakane, A., & Hu, D. L. (2019).
Staphylococcal enterotoxin C is an important virulence factor for mastitis. Toxins, 11(3), 141.
https://doi.org/10.3390/toxins11030141

Fisher, E. L., Otto, M., & Cheung, G. Y. C. (2018). Basis of virulence in enterotoxin-mediated staphylococcal
food poisoning. Frontiers in Microbiology, 9(MAR), 436. https://doi.org/10.3389/fmicb.2018.00436

Fitzgerald, J. R., Monday, S. R., Foster, T. J., Bohach, G. A., Hartigan, P. J., Meaney, W. J., & Smyth, C. J. (2001).
Characterization of a putative pathogenicity island from bovine Staphylococcus aureus encoding multiple
superantigens. Journal of Bacteriology, 183(1), 63–70. https://doi.org/10.1128/jb.183.1.63-70.2001

Fleischer, B., & Fleischer, B. (1994). Superantigens. APMIS, 102(1–6), 3–12. https://doi.org/10.1111/J.1699-
0463.1994.TB04839.X

Günther, S., Varma, A. K., Moza, B., Kasper, K. J., Wyatt, A. W., Zhu, P., Rahman, A. K. M. N. ur, Li, Y., Mariuzza,
R. A., McCormick, J. K., & Sundberg, E. J. (2007). A novel loop domain in superantigens extends their T
cell receptor recognition site. Journal of Molecular Biology, 371(1), 210–221.
https://doi.org/10.1016/j.jmb.2007.05.038

GUSS, B., UHLÉN, M., NILSSON, B., LINDBERG, M., SJÖQUIST, J., & SJÖDAHL, J. (1984). Region X, the cell-wall-
attachment part of staphylococcal protein a. European Journal of Biochemistry, 138(2), 413–420.
https://doi.org/10.1111/j.1432-1033.1984.tb07931.x

Hall, M., Hoyt, L., Ferrieri, P., Schlievert, P. M., & Jenson, H. B. (1999). Kawasaki syndrome-like illness
associated with infection caused by enterotoxin B-secreting Staphylococcus aureus. Clinical Infectious
Diseases, 29(3), 586–589. https://doi.org/10.1086/598638

Haveri, M., Taponen, S., Vuopio-Varkila, J., Salmenlinna, S., & Pyörälä, S. (2005). Bacterial genotype affects the
manifestation and persistence of bovine Staphylococcus aureus intramammary infection. Journal of
Clinical Microbiology, 43(2), 959–961. https://doi.org/10.1128/jcm.43.2.959-961.2005
Hoekstra, J., Zomer, A. L., Rutten, V. P. M. G., Benedictus, L., Stegeman, A., Spaninks, M. P., Bennedsgaard, T.
W., Biggs, A., De Vliegher, S., Mateo, D. H., Huber-Schlenstedt, R., Katholm, J., Kovács, P., Krömker, V.,
Lequeux, G., Moroni, P., Pinho, L., Smulski, S., Supré, K., … Koop, G. (2020). Genomic analysis of European
bovine Staphylococcus aureus from clinical versus subclinical mastitis. Scientific Reports, 10(1), 18172.
https://doi.org/10.1038/s41598-020-75179-2

Hu, D. L., Omoe, K., Sasaki, S., Sashinami, H., Sakuraba, H., Yokomizo, Y., Shinagawa, K., & Nakane, A. (2003).
Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus
infection. The Journal of Infectious Diseases, 188(5), 743–752. https://doi.org/10.1086/377308

Hu, D. L., Zhu, G., Mori, F., Omoe, K., Okada, M., Wakabayashi, K., Kaneko, S., Shinagawa, K., & Nakane, A.
(2007). Staphylococcal enterotoxin induces emesis through increasing serotonin release in intestine and
it is downregulated by cannabinoid receptor 1. Cellular Microbiology, 9(9), 2267–2277.
https://doi.org/10.1111/j.1462-5822.2007.00957.x

Jiang, K., Guo, S., Yang, J., Liu, J., Shaukat, A., Zhao, G., Wu, H., & Deng, G. (2019). Matrine alleviates
Staphylococcus aureus lipoteichoic acid-induced endometritis via suppression of TLR2-mediated NF-κB
activation. International Immunopharmacology, 70, 201–207.
https://doi.org/10.1016/j.intimp.2019.02.033

Jupin, C., Anderson, S., Damais, C., Alouf, J. E., & Parant, M. (1988). Toxic shock syndrome toxin 1 as an inducer
of human tumor necrosis factors and gamma interferon. The Journal of Experimental Medicine, 167(3),
752–761. https://doi.org/10.1084/jem.167.3.752

Kappler, J., Kotzin, B., Herron, L., Gelfand, E. W., Bigler, R. D., Boylston, A., Carrel, S., Posnett, D. N., Choi, Y., &
Marrack, P. (1989). V beta-specific stimulation of human T cells by staphylococcal toxins. Science,
244(4906), 811–813. https://doi.org/10.1126/science.2524876

Kato, M., Nakamura, Y., Suda, T., Ozawa, Y., Inui, N., Seo, N., Nagata, T., Koide, Y., Kalinski, P., Nakamura, H., &
Chida, K. (2011). Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells. Cancer
Immunology, Immunotherapy, 60(7), 1029–1038. https://doi.org/10.1007/s00262-011-1015-5

Katsuda, K., Hata, E., Kobayashi, H., Kohmoto, M., Kawashima, K., Tsunemitsu, H., & Eguchi, M. (2005).
Molecular typing of Staphylococcus aureus isolated from bovine mastitic milk on the basis of toxin genes
and coagulase gene polymorphisms. Veterinary Microbiology, 105(3/4), 301–305.
https://doi.org/10.1016/j.vetmic.2004.12.004

Kérouanton, A., Hennekinne, J. A., Letertre, C., Petit, L., Chesneau, O., Brisabois, A., & De Buyser, M. L. (2007).
Characterization of Staphylococcus aureus strains associated with food poisoning outbreaks in France.
International Journal of Food Microbiology, 115(3), 369–375.
https://doi.org/10.1016/j.ijfoodmicro.2006.10.050

Kim, J., Kim, B. E., Ahn, K., & Leung, D. Y. M. (2019). Interactions between atopic dermatitis and
Staphylococcus aureus infection: Clinical implications. Allergy, Asthma & Immunology Research, 11(5),
593–603. https://doi.org/10.4168/aair.2019.11.5.593

Kozono, H., Parker, D., White, J., Marrack, P., & Kappler, J. (1995). Multiple binding sites for bacterial
superantigens on soluble class II MHC molecules. Immunity, 3(2), 187–196.
https://doi.org/10.1016/1074-7613(95)90088-8
Krakauer, T. (2019). Staphylococcal superantigens: Pyrogenic toxins induce toxic shock. Toxins, 11(3), 178.
https://doi.org/10.3390/toxins11030178

L Mojahed Asl, K. S. M. N. (2019). Comparison of relation between resistance pattern to erythromycin and
tetracycline and the prevalence of superantigens coding enterotoxins A and B in Staphylococcus aureus
isolated from broiler poultry in Ilam, Iran. Archives of Razi Institute, 74(2), 157–164.
https://doi.org/10.22092/ari.2018.116231.1161

Lee, P. K., Vercellotti, G. M., Deringer, J. R., & Schlievert, P. M. (1991). Effects of staphylococcal toxic shock
syndrome toxin 1 on aortic endothelial cells. The Journal of Infectious Diseases, 164(4), 711–719.
https://doi.org/10.1093/infdis/164.4.711

Leuenberger, A., Sartori, C., Boss, R., Resch, G., Oechslin, F., Steiner, A., Moreillon, P., & Graber, H. U. (2019).
Genotypes of Staphylococcus aureus: On-farm epidemiology and the consequences for prevention of
intramammary infections. Journal of Dairy Science, 102(4), 3295–3309.
https://doi.org/10.3168/jds.2018-15181

Leung, D. Y. M., Gately, M., Trumble, A., Ferguson-Darnell, B., Schlievert, P. M., & Picker, L. J. (1995). Bacterial
superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-
associated antigen, via stimulation of interleukin 12 production. The Journal of Experimental Medicine,
181(2), 747–753. https://doi.org/10.1084/jem.181.2.747

Li, S. J., Hu, D. L., Maina, E. K., Shinagawa, K., Omoe, K., & Nakane, A. (2011a). Superantigenic activity of toxic
shock syndrome toxin-1 is resistant to heating and digestive enzymes. Journal of Applied Microbiology,
110(3), 729–736. https://doi.org/10.1111/j.1365-2672.2010.04927.x

Li, S. J., Hu, D. L., Maina, E. K., Shinagawa, K., Omoe, K., & Nakane, A. (2011b). Superantigenic activity of toxic
shock syndrome toxin-1 is resistant to heating and digestive enzymes. Journal of Applied Microbiology,
110(3), 729–736. https://doi.org/10.1111/J.1365-2672.2010.04927.X

Li, T., Lu, H., Wang, X., Gao, Q., Dai, Y., Shang, J., & Li, M. (2017). Molecular characteristics of Staphylococcus
aureus causing bovine mastitis between 2014 and 2015. Frontiers in Cellular and Infection Microbiology,
7(APR), 127. https://doi.org/10.3389/fcimb.2017.00127

Ma, W., Yu, H., Wang, Q., Jin, H., Solheim, J., & Labhasetwar, V. (2004). A novel approach for cancer
immunotherapy: Tumor cells with anchored superantigen SEA generate effective antitumor immunity.
Journal of Clinical Immunology, 24(3), 294–301. https://doi.org/10.1023/b:joci.0000025451.41948.94

Maina, E. K., Hu, D. L., Tsuji, T., Omoe, K., & Nakane, A. (2012). Staphylococcal enterotoxin A has potent
superantigenic and emetic activities but not diarrheagenic activity. International Journal of Medical
Microbiology, 302(2), 88–95. https://doi.org/10.1016/j.ijmm.2012.01.003

Martín, M. C., Fueyo, J. M., González-Hevia, M. A., & Mendoza, M. C. (2004). Genetic procedures for
identification of enterotoxigenic strains of Staphylococcus aureus from three food poisoning outbreaks.
International Journal of Food Microbiology, 94(3), 279–286.
https://doi.org/10.1016/j.ijfoodmicro.2004.01.011
Matsubara, K., & Fukaya, T. (2007). The role of superantigens of group a Streptococcus and Staphylococcus
aureus in Kawasaki disease. Current Opinion in Infectious Diseases, 20(3), 298–303.
https://doi.org/10.1097/qco.0b013e3280964d8c

Mattis, D. M., Spaulding, A. R., Chuang-Smith, O. N., Sundberg, E. J., Schlievert, P. M., & Kranz, D. M. (2013).
Engineering a soluble high-affinity receptor domain that neutralizes staphylococcal enterotoxin C in
rabbit models of disease. Protein Engineering, Design & Selection, 26(2), 133–142.
https://doi.org/10.1093/protein/gzs094

McCormick, J. K., Yarwood, J. M., & Schlievert, P. M. (2001). Toxic shock syndrome and bacterial superantigens:
An update. Annual Review of Microbiology, 55, 77–104. https://doi.org/10.1146/annurev.micro.55.1.77

McKay, D. M., Botelho, F., Ceponis, P. J. M., & Richards, C. D. (2000). Superantigen immune stimulation
activates epithelial STAT-1 and PI 3-K: PI 3-K regulation of permeability. American Journal of Physiology.
Gastrointestinal and Liver Physiology, 279(5), G1094–G1103.
https://doi.org/10.1152/ajpgi.2000.279.5.g1094

Miller, L. S., Fowler, V. G., Shukla, S. K., Rose, W. E., & Proctor, R. A. (2020). Development of a vaccine against
Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial
evasion mechanisms. FEMS Microbiology Reviews, 44(1), 123–153.
https://doi.org/10.1093/femsre/fuz030

Miwa, K., Fukuyama, M., Matsuno, N., Masuda, S., Oyama, Y., Ikeda, K., & Ikeda, T. (2006). Superantigen-
induced multiple organ dysfunction in a toxin-concentration-controlled and sequential parameter-
monitored swine Sepsis model. International Journal of Infectious Diseases, 10(1), 14–24.
https://doi.org/10.1016/j.ijid.2005.01.006

Pascual, V., & Capra, J. D. (1991). B-cell superantigens? Current Biology, 1(5), 315–317.
https://doi.org/10.1016/0960-9822(91)90097-G